Search

Displaying results 4321 - 4330 of 10000 in total
  1. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain. … XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef.

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma … to be approved by the FDA.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents
  4. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    It is an inhibitor of the A subunit of bacterial DNA gyrase.

  5. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Swiss One Multivitamin and Mineral Caplet, Vita Vim Multivitamins and Minerals TabCategories: Amino Acids, Peptides, and Proteins
  6. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms.

    Categories: Antineoplastic and Immunomodulating Agents
  7. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    nausea and vomiting. … Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

    Categories: Alimentary Tract and Metabolism, Antiemetics and Antinauseants
  8. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

    Categories: Beta Blocking Agents and Thiazides, Antiglaucoma Preparations and Miotics
  9. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The balance between potassium and sodium is maintained by ion pumps in the cell membrane. … The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge.

  10. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] Sevabertinib was granted accelerated approval by the FDA on November 19th, 2025 for patients who had received a prior systemic therapy.

    Categories: MATE 2-K Inhibitors